Skip to content

Study · Randomized controlled trial · n = 54 · 2020

8 results

Dulaglutide-combined basal plus correction insulin therapy contributes to ideal glycemic control in non-critical hospitalized patients.

Fushimi N, Shibuya T, Yoshida Y, Ito S, Hachiya H, Mori A

Journal of diabetes investigation28 Jun 2019Cited by 29 (Europe PMC)

PMID31168938 (opens in a new tab)PMCIDPMC6944833 (opens in a new tab)DOI10.1111/jdi.13093 (opens in a new tab)PepBankPUB-31168938
Download PDFPubMedAsk about this study
Jump to 8 results

Summary

Aims/introductionWe investigated whether dulaglutide (DU)-combined conventional insulin therapy is beneficial for glycemic control in non-critically ill hospitalized patients with type 2 diabetes.Materials and methodsThis study was a prospective, randomized controlled pilot study. Participants were randomized to either basal-plus (BP) therapy, where basal insulin and corrective doses of regular insulin were administered before meals, or BP + DU therapy, where BP therapy was combined with DU. Blood glucose (BG) levels before and after every meal were measured for 7 days after assignment to groups. Because we consider the ideal BG during hospitalization to be within 100-180 mg/dL, we defined this range as the hospitalized ideal glucose range (hIGR). We compared the percentage of BG measurements within the hIGR among all BG measurements (%hIGR), mean BG, glucose variability and insulin dose between the two groups.ResultsOf 54 patients, 27 were assigned to the BP group and 27 to the BP + DU group. The %hIGR was significantly higher (44% vs 56%, P 240 mg/dL and BG <70 mg/dL was significantly lower in the BP + DU group than in the BP group (both P < 0.001). The mean BG (183 ± 29 vs 162 ± 30 mg/dL, P < 0.05), standard deviation (P < 0.01), coefficient of variation (P < 0.01) and total regular insulin dose (P < 0.05) in the BP + DU group were significantly lower than those in the BP group. No significant side-effects were observed in either group.ConclusionsBP + DU therapy reduced the frequency of hyperglycemia and hypoglycemia, and resulted in a lower glucose variability.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In hospitalized patients with diabetes, adding dulaglutide increased glucose measurements in the ideal range versus basal-plus insulin alone.

    In plain wordsIn hospitalized patients with diabetes, adding dulaglutide increased readings in the ideal blood sugar range compared with insulin alone.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseGlucose measurements in ideal range
    Study

    n = 54

    Comparator
    Basal-plus insulin alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 7 daysAs given in this study (human).

    Measurements

    Glucose measurements within ideal range
    44%
    basal-plus insulin
    Glucose measurements within ideal range
    56%
    dulaglutide plus basal-plus insulin

    Source sentences

    Summary
    The %hIGR was significantly higher (44% vs 56%, P 240 mg/dL and BG <70 mg/dL was significantly lower in the BP + DU group than in the BP group (both P < 0.001).
    5 context sentences
    Summary · context
    Because we consider the ideal BG during hospitalization to be within 100-180 mg/dL, we defined this range as the hospitalized ideal glucose range (hIGR).
    Summary · context
    We investigated whether dulaglutide (DU)-combined conventional insulin therapy is beneficial for glycemic control in non-critically ill hospitalized patients with type 2 diabetes.
    Summary · context
    This study was a prospective, randomized controlled pilot study.
    Summary · context
    Participants were randomized to either basal-plus (BP) therapy, where basal insulin and corrective doses of regular insulin were administered before meals, or BP + DU therapy, where BP therapy was combined with DU.
    Summary · context
    Blood glucose (BG) levels before and after every meal were measured for 7 days after assignment to groups.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In hospitalized patients with diabetes, adding dulaglutide reduced glucose readings above 240 mg/dL versus basal-plus insulin alone.

    In plain wordsIn hospitalized patients with diabetes, adding dulaglutide reduced high blood sugar readings compared with insulin alone.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseGlucose above 240 mg/dL
    Study

    n = 54

    Comparator
    Basal-plus insulin alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 7 daysAs given in this study (human).

    Source sentences

    Summary
    The %hIGR was significantly higher (44% vs 56%, P 240 mg/dL and BG <70 mg/dL was significantly lower in the BP + DU group than in the BP group (both P < 0.001).
    4 context sentences
    Summary · context
    We investigated whether dulaglutide (DU)-combined conventional insulin therapy is beneficial for glycemic control in non-critically ill hospitalized patients with type 2 diabetes.
    Summary · context
    This study was a prospective, randomized controlled pilot study.
    Summary · context
    Participants were randomized to either basal-plus (BP) therapy, where basal insulin and corrective doses of regular insulin were administered before meals, or BP + DU therapy, where BP therapy was combined with DU.
    Summary · context
    Blood glucose (BG) levels before and after every meal were measured for 7 days after assignment to groups.
  3. 03HumanRandomized controlled trialSafety outcome

    In hospitalized patients with diabetes, adding dulaglutide reduced glucose readings below 70 mg/dL versus basal-plus insulin alone.

    In plain wordsIn hospitalized patients with diabetes, adding dulaglutide reduced low blood sugar readings compared with insulin alone.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseGlucose below 70 mg/dL
    Study

    n = 54

    Comparator
    Basal-plus insulin alone
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated · 7 daysAs given in this study (human).

    Source sentences

    Summary
    The %hIGR was significantly higher (44% vs 56%, P 240 mg/dL and BG <70 mg/dL was significantly lower in the BP + DU group than in the BP group (both P < 0.001).
    4 context sentences
    Summary · context
    We investigated whether dulaglutide (DU)-combined conventional insulin therapy is beneficial for glycemic control in non-critically ill hospitalized patients with type 2 diabetes.
    Summary · context
    This study was a prospective, randomized controlled pilot study.
    Summary · context
    Participants were randomized to either basal-plus (BP) therapy, where basal insulin and corrective doses of regular insulin were administered before meals, or BP + DU therapy, where BP therapy was combined with DU.
    Summary · context
    Blood glucose (BG) levels before and after every meal were measured for 7 days after assignment to groups.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In hospitalized patients with diabetes, adding dulaglutide lowered mean glucose versus basal-plus insulin alone.

    In plain wordsIn hospitalized patients with diabetes, adding dulaglutide lowered average blood sugar compared with insulin alone.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseMean blood glucose
    Study

    n = 54

    Comparator
    Basal-plus insulin alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 7 daysAs given in this study (human).

    Measurements

    Mean glucose
    162 mg/dL
    dulaglutide plus basal-plus insulin
    Mean glucose
    183 mg/dL
    basal-plus insulin

    Source sentences

    Summary
    The mean BG (183 ± 29 vs 162 ± 30 mg/dL, P < 0.05), standard deviation (P < 0.01), coefficient of variation (P < 0.01) and total regular insulin dose (P < 0.05) in the BP + DU group were significantly lower than those in the BP group.
    4 context sentences
    Summary · context
    We investigated whether dulaglutide (DU)-combined conventional insulin therapy is beneficial for glycemic control in non-critically ill hospitalized patients with type 2 diabetes.
    Summary · context
    This study was a prospective, randomized controlled pilot study.
    Summary · context
    Participants were randomized to either basal-plus (BP) therapy, where basal insulin and corrective doses of regular insulin were administered before meals, or BP + DU therapy, where BP therapy was combined with DU.
    Summary · context
    Blood glucose (BG) levels before and after every meal were measured for 7 days after assignment to groups.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In hospitalized patients with diabetes, adding dulaglutide lowered glucose standard deviation versus basal-plus insulin alone.

    In plain wordsIn hospitalized patients with diabetes, adding dulaglutide reduced blood sugar variation compared with insulin alone.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseGlucose standard deviation
    Study

    n = 54

    Comparator
    Basal-plus insulin alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 7 daysAs given in this study (human).

    Source sentences

    Summary
    The mean BG (183 ± 29 vs 162 ± 30 mg/dL, P < 0.05), standard deviation (P < 0.01), coefficient of variation (P < 0.01) and total regular insulin dose (P < 0.05) in the BP + DU group were significantly lower than those in the BP group.
    4 context sentences
    Summary · context
    We investigated whether dulaglutide (DU)-combined conventional insulin therapy is beneficial for glycemic control in non-critically ill hospitalized patients with type 2 diabetes.
    Summary · context
    This study was a prospective, randomized controlled pilot study.
    Summary · context
    Participants were randomized to either basal-plus (BP) therapy, where basal insulin and corrective doses of regular insulin were administered before meals, or BP + DU therapy, where BP therapy was combined with DU.
    Summary · context
    Blood glucose (BG) levels before and after every meal were measured for 7 days after assignment to groups.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In hospitalized patients with diabetes, adding dulaglutide lowered glucose coefficient of variation versus basal-plus insulin alone.

    In plain wordsIn hospitalized patients with diabetes, adding dulaglutide reduced relative blood sugar variation compared with insulin alone.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseGlucose coefficient of variation
    Study

    n = 54

    Comparator
    Basal-plus insulin alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 7 daysAs given in this study (human).

    Source sentences

    Summary
    The mean BG (183 ± 29 vs 162 ± 30 mg/dL, P < 0.05), standard deviation (P < 0.01), coefficient of variation (P < 0.01) and total regular insulin dose (P < 0.05) in the BP + DU group were significantly lower than those in the BP group.
    4 context sentences
    Summary · context
    We investigated whether dulaglutide (DU)-combined conventional insulin therapy is beneficial for glycemic control in non-critically ill hospitalized patients with type 2 diabetes.
    Summary · context
    This study was a prospective, randomized controlled pilot study.
    Summary · context
    Participants were randomized to either basal-plus (BP) therapy, where basal insulin and corrective doses of regular insulin were administered before meals, or BP + DU therapy, where BP therapy was combined with DU.
    Summary · context
    Blood glucose (BG) levels before and after every meal were measured for 7 days after assignment to groups.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In hospitalized patients with diabetes, adding dulaglutide reduced total regular insulin dose versus basal-plus insulin alone.

    In plain wordsIn hospitalized patients with diabetes, adding dulaglutide reduced regular insulin requirements compared with insulin alone.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseRegular insulin dose
    Study

    n = 54

    Comparator
    Basal-plus insulin alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 7 daysAs given in this study (human).

    Source sentences

    Summary
    The mean BG (183 ± 29 vs 162 ± 30 mg/dL, P < 0.05), standard deviation (P < 0.01), coefficient of variation (P < 0.01) and total regular insulin dose (P < 0.05) in the BP + DU group were significantly lower than those in the BP group.
    4 context sentences
    Summary · context
    We investigated whether dulaglutide (DU)-combined conventional insulin therapy is beneficial for glycemic control in non-critically ill hospitalized patients with type 2 diabetes.
    Summary · context
    This study was a prospective, randomized controlled pilot study.
    Summary · context
    Participants were randomized to either basal-plus (BP) therapy, where basal insulin and corrective doses of regular insulin were administered before meals, or BP + DU therapy, where BP therapy was combined with DU.
    Summary · context
    Blood glucose (BG) levels before and after every meal were measured for 7 days after assignment to groups.
  8. 08HumanRandomized controlled trialSafety outcome

    In hospitalized patients with diabetes, neither dulaglutide plus basal-plus insulin nor basal-plus insulin alone produced significant side effects.

    In plain wordsIn hospitalized patients with diabetes, neither dulaglutide with insulin nor insulin alone produced significant side effects.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableSignificant side effects
    Study

    n = 54

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · 7 daysAs given in this study (human).

    Source sentences

    Summary
    No significant side-effects were observed in either group.
    4 context sentences
    Summary · context
    We investigated whether dulaglutide (DU)-combined conventional insulin therapy is beneficial for glycemic control in non-critically ill hospitalized patients with type 2 diabetes.
    Summary · context
    This study was a prospective, randomized controlled pilot study.
    Summary · context
    Participants were randomized to either basal-plus (BP) therapy, where basal insulin and corrective doses of regular insulin were administered before meals, or BP + DU therapy, where BP therapy was combined with DU.
    Summary · context
    Blood glucose (BG) levels before and after every meal were measured for 7 days after assignment to groups.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.